CN101361750A - Use of naringin in preparing antiatherosclerotic medicine - Google Patents
Use of naringin in preparing antiatherosclerotic medicine Download PDFInfo
- Publication number
- CN101361750A CN101361750A CNA2008101987778A CN200810198777A CN101361750A CN 101361750 A CN101361750 A CN 101361750A CN A2008101987778 A CNA2008101987778 A CN A2008101987778A CN 200810198777 A CN200810198777 A CN 200810198777A CN 101361750 A CN101361750 A CN 101361750A
- Authority
- CN
- China
- Prior art keywords
- naringin
- serum
- level
- atherosclerosis
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses an application of naringin in preparing medicaments for curing atherosclerosis. Tests prove that the naringin can decrease level of serum cholesterol, inhibit cholesterin on arterial vascular walls from depositing, obviously decrease level of serum TC, TG, LDL-C, remarkably raise level of serum HDL-C, improve activity of serum SOD and increase level of NO, obviously decrease level of MDA, effectively prevent atheromatous plaques from being formed or damaged, and have the obvious function of curing atherosclerosis.
Description
Technical field
The present invention relates to naringin, be specifically related to a kind of new drug purposes of naringin.
Background technology
The caused coronary heart disease of atherosclerosis, cerebrovascular and peripheral vascular disease, the serious harm human health, its M ﹠ M all occupies the various diseases prostatitis.According to Epidemiological study, cardiovascular and cerebrovascular disease is about 5～6% at global sickness rate, near 10%, seizes 1,200 ten thousand people's life every year, near 1/4 of the total death toll of world population at the sickness rate of some developed country.Be used for atherosclerosis control and thus due to the medical expense of cardiovascular and cerebrovascular disease be annual 40000000000 dollars.China cardiovascular and cerebrovascular vessel patient has 7,000 ten thousand people, there is the people of atherosclerotic lesion then more, and prevalence, the sickness rate of this disease are in rising trend, it is on a declining curve that atherosclerosis takes place by the age, therefore at atherosclerotic pathogeny, for the Antiatherosclerosis medicine that satisfies growing clinical needs exploitation will have vast market.
Atherosclerosis (AS) is the able-bodied diseases of a kind of common but severe harm people, can cause the generation of coronary heart disease, cerebrovascular and peripheral vascular disease.Therefore, the searching Antiatherosclerosis medicine is the hot subject in the cardiovascular field always.
Atherosclerosis is a kind of common cardiovascular disease, and is closely connected with coronary heart disease, hypertension, apoplexy.The sickness rate height of China's cardiovascular disease, serious harm human healthy, and brought huge economic pressures and burden to society.Therefore research and development are used for hyperlipidemia disease, atheromatous medicine, and extensive market prospects and social meaning are arranged.
Naringin, naringin derives from the fruit of Citrus paradisi Macfadyen, grapefruit, Citrus aurantium L. Var decumana Bonar or Poncirus trifoliata Raf., and the leaves of Sterculiaceae plant Radix Flemingiae Philippinensis etc. also do not have naringin to be used for antiatherogenic report at present.
Summary of the invention
The purpose of this invention is to provide a kind of naringin is used for atherosclerosis relevant disease medicine in preparation application.
The present invention discovers that the described naringin of formula (I) can reduce serum cholesterol content, can suppress the deposition of arterial blood tube wall cholesterol simultaneously again, thus atherosclerosis.
The present invention's research finds that also naringin can obviously reduce serum TC, TG, the reduction of LDL-C level, simultaneously the remarkable elevating HDL-C level of energy; Activity of SOD in serum and NO content can be improved, MDA content can be obviously reduced simultaneously; Can obviously reduce simultaneously the formation and the damage of atheromatous plaque.The prompting naringin has obvious antiatherogenic effect.
The specific embodiment
Below the invention will be further described by specific embodiment.
Embodiment 1: naringin is to the influence of experimental atherosclerosis rabbit anteserum and arterial blood tube wall cholesterol
Get 48 of healthy new zealand white rabbits, male and female half and half, body weight (2.0 ± 0.2) kg is divided into the normal control group at random, Atherosclerosis Model group, positive drug (cholestyramine) matched group, naringin low dose group, dosage group in the naringin, naringin high dose group.Except that normal control group normal diet normal diet, all the other each groups all adopt high lipid food (3% cholesterol, 5% Adeps Sus domestica, 5% yolk powder, 0.2% methylthiouracil, 87% normal feedstuff) to feed.Feed also continuously and gavage medicine simultaneously after 60 days, get animal aorta and serum, measure arterial blood tube wall and serum cholesterol content.Experimental result sees Table 1.
Table 1 naringin is to the influence of experimental atherosclerosis rabbit tremulous pulse serum and arterial blood tube wall cholesterol level
Annotate: compare with the normal control group:
##P＜0.01; Compare with model control group:
*P＜0.05
*P＜0.01
By table 1 as seen, the arterial blood tube wall of the basic, normal, high dosage group of naringin and serum cholesterol content and Atherosclerosis Model group are relatively, difference has statistical significance, the prompting naringin can reduce serum cholesterol content, the deposition that can suppress arterial blood tube wall cholesterol simultaneously again, thereby atherosclerosis.
Embodiment 2: naringin is to the atherosclerotic influence of rabbit experiment
Get 48 of healthy new zealand white rabbits, male and female half and half, body weight (2.0 ± 0.2) kg, be divided into the normal control group at random, Atherosclerosis Model group, positive drug (simvastatin) matched group, the naringin low dose group, dosage group in the naringin, naringin high dose group.Except that normal control group normal diet normal diet, all the other each groups all adopt high lipid food (3% cholesterol, 5% Adeps Sus domestica, 5% yolk powder, 0.2% methylthiouracil, 87% normal feedstuff) to feed.Feed also continuously and gavage medicine simultaneously after 60 days, get fasting blood and on automatic clinical chemistry analyzer, measure the content of serum total cholesterol (TC), triglyceride (TG), HDL-C (HDL-C), low-density lipoprotein cholesterol (LDL-C) respectively, detect serum superoxide dismutases (SOD) vigor and malonaldehyde (MDA), nitric oxide (NO) content with test kit, put to death animal subsequently, get aorta and do the pathomorphology inspection.Experimental result sees Table 2,3.
By table 2 as seen, the serum total cholesterol (TC) of the basic, normal, high dosage group of naringin, triglyceride (TG), HDL-C (HDL-C), low-density lipoprotein cholesterol (LDL-C) content and Atherosclerosis Model group are relatively, difference has statistical significance, the prompting naringin can obviously reduce serum TC, TG, the LDL-C level reduces, simultaneously can remarkable elevating HDL-C level.
By table 3 as seen, the activity of SOD in serum of the basic, normal, high dosage group of naringin, MDA content, NO content and Atherosclerosis Model group are relatively, difference has statistical significance, and the prompting naringin can improve activity of SOD in serum and NO content, can obviously reduce MDA content simultaneously.
The morphological examination of aorta pathology is the result show: the rats in normal control group aortic tunica intima is smooth smooth, and it is greyish white that color is, and not seeing has abnormality.Model group rat aorta visible vessels inner membrance is distributed with yellow speckle in various degree, and is more obvious with aortic arch, thoracic aorta and aortic arch crotch.Simvastatin group pathological changes is lighter, be confined to aortic arch and aorta crotch; pathological changes is based on strip and streak speckle; naringin is basic, normal, high, and respectively to organize the rat pathological changes also lighter; pathological changes disperses to be aortic arch and crotch with strip, streak speckle, and lesion degree alleviates with the increase of naringin dosage.
This experimental result shows that naringin can obviously reduce serum TC, TG, and the LDL-C level reduces, simultaneously the remarkable elevating HDL-C level of energy; Activity of SOD in serum and NO content can be improved, MDA content can be obviously reduced simultaneously; Can obviously reduce simultaneously the formation and the damage of atheromatous plaque.The prompting naringin has obvious antiatherogenic effect.
Table 2 naringin is to the influence of experimental atherosclerosis rabbit anteserum lipid
Annotate: compare with the normal control group:
##P＜0.01; Compare with model control group:
*P＜0.05
*P＜0.01
Table 3 naringin is to the influence of experimental atherosclerosis rabbit anteserum SOD, MDA, NO
Annotate: compare with the normal control group:
##P＜0.01; Compare with model control group:
*P＜0.05
*P＜0.01
Claims (1)
1. naringin shown in the formula (I) is used for the application of Antiatherosclerosis medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101987778A CN101361750A (en) | 2008-09-26 | 2008-09-26 | Use of naringin in preparing antiatherosclerotic medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101987778A CN101361750A (en) | 2008-09-26 | 2008-09-26 | Use of naringin in preparing antiatherosclerotic medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101361750A true CN101361750A (en) | 2009-02-11 |
Family
ID=40388478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008101987778A Pending CN101361750A (en) | 2008-09-26 | 2008-09-26 | Use of naringin in preparing antiatherosclerotic medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101361750A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111227247A (en) * | 2020-03-10 | 2020-06-05 | 中国农业科学院农产品加工研究所 | Citrus product with functions of improving intestinal flora structure and relieving atherosclerosis as well as preparation method and application of citrus product |
-
2008
- 2008-09-26 CN CNA2008101987778A patent/CN101361750A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111227247A (en) * | 2020-03-10 | 2020-06-05 | 中国农业科学院农产品加工研究所 | Citrus product with functions of improving intestinal flora structure and relieving atherosclerosis as well as preparation method and application of citrus product |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101715913B (en) | Capsule for regulating blood fat and production process thereof | |
| CN103446174B (en) | Oligomannuronic acid is preparing the application in the medicine of prevention and therapy alcoholic liver injury, health product or dietary supplement | |
| CN107441078A (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
| CN103007208B (en) | Traditional Chinese medicine formula for preventing fatty liver hemorrhagic syndrome of broiler chickens | |
| CN105963254A (en) | Coenzyme Q10 pharmaceutical composition and preparation process thereof | |
| CN103893306B (en) | A kind of blackberry seed effective ingredient and extracting method thereof, application | |
| JP2012067023A (en) | Composition for improving biofunction containing essence of cistanche deserticola y. c. ma | |
| CN101361750A (en) | Use of naringin in preparing antiatherosclerotic medicine | |
| TW201006389A (en) | Formulations, methods and its use for reducing abdominal fat and waist circumference | |
| CN106562165A (en) | Slimming type blended fruit-vegetable juice drink and preparation method thereof | |
| CN106617076A (en) | Composition for assisting in reducing blood lipid, preparation method of composition, and health-care food including composition | |
| CN114432337B (en) | Application of cordyceps guangdongensis fruiting body polysaccharide in preparation of medicine for treating and improving obesity and related diseases | |
| JP7340113B2 (en) | Chinese herbal composition and its production method and use | |
| WO2019100843A1 (en) | Enteromorpha prolifera polysaccharide composite blood lipid-lowering health care product and preparation method therefor | |
| CN103735550A (en) | Medicinal composition for treating CKD (chronic kidney disease) myocardial injury and application thereof | |
| CN1583108A (en) | Health care product of hippophae rhamnoides oil | |
| CN104173346B (en) | A kind of compositions containing sodium ferulate | |
| JP2013063941A (en) | Prophylactic or improving agent of irritable bowel syndrome | |
| CN104127545B (en) | New application of murraya tetramera huang and extract thereof in preparation of medicines | |
| KR100595459B1 (en) | Composition for inhibiting obesity | |
| CN101461802A (en) | Application of epi-gallocatechin-3-gallate in preparing medicament for preventing and treating high-fat fatty liver | |
| CN101837104B (en) | Hyperlipidemia treating capsules | |
| CN103652885A (en) | Health-care food capable of regulating hyperlipidemia | |
| CN110292607A (en) | The Chinese medicine composition and preparation method for treating the concurrent left ventricular hypertrophy of high blood pressure | |
| CN106822114B (en) | Application of MTCA in preparation of medicines for reducing blood sugar or blood fat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090211 |